Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Short-term Investments (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Short-term Investments data on record, last reported at $560000.0 in Q4 2025.

  • For Q4 2025, Short-term Investments changed N/A year-over-year to $560000.0; the TTM value through Dec 2025 reached $560000.0, changed N/A, while the annual FY2025 figure was $560000.0, N/A changed from the prior year.
  • Short-term Investments reached $560000.0 in Q4 2025 per TARS's latest filing, down from $289.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $289.1 million in Q3 2025 and bottomed at $20000.0 in Q1 2021.
  • Average Short-term Investments over 5 years is $101.7 million, with a median of $88.1 million recorded in 2023.
  • The widest YoY moves for Short-term Investments: up 46368.04% in 2023, down 98.28% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $483000.0 in 2021, then surged by 29996.48% to $145.4 million in 2022, then plummeted by 98.28% to $2.5 million in 2023, then surged by 5540.96% to $140.7 million in 2024, then plummeted by 99.6% to $560000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $560000.0 in Q4 2025, $289.1 million in Q3 2025, and $284.5 million in Q2 2025.